MorphoSys reports additional Phase I/IIa data of MOR202 in MM

MorphoSys AG (Xetra:MOR; Pink:MPSYY) reported additional data from an open-label, dose-escalation, Austrian and German Phase I/IIa trial evaluating MOR202 (MOR03087) in patients with relapsed or refractory multiple myeloma (MM). In 18 evaluable patients, once-weekly IV MOR202 plus low-dose dexamethasone led to an objective response rate (ORR) of 28%. Median progression-free survival (PFS) was 4.7 months at a median follow-up of 22.1 months.

In 17 evaluable patients, once-weekly IV MOR202 plus low-dose dexamethasone and Revlimid lenalidomide led to an ORR of 71%, including 1 complete response, 3 very good partial responses and 8 partial responses. Median PFS has not yet been reached at a median follow-up of 7.5 months...